Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
0.00
0.00 (0.00%)
May 12, 2026, 1:58 PM EDT - Market open
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 3 analysts that cover Bio-Rad Laboratories stock have a consensus rating of "Hold" and an average price target of $333, which forecasts no change in the stock price over the next year. The lowest target is $290 and the highest is $409.
Price Target: $333 (0.00%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $320 → $290 | Hold | Maintains | $320 → $290 | n/a | May 1, 2026 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $375 → $300 | Strong Buy → Hold | Downgrades | $375 → $300 | n/a | Apr 7, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $350 → $375 | Strong Buy | Maintains | $350 → $375 | n/a | Oct 30, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $265 → $340 | Hold | Maintains | $265 → $340 | n/a | Oct 30, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $387 → $409 | Buy | Maintains | $387 → $409 | n/a | Aug 1, 2025 |
Financial Forecast
Revenue This Year
2.60B
from 2.58B
Increased by 0.57%
Revenue Next Year
2.66B
from 2.60B
Increased by 2.39%
EPS This Year
9.48
from 27.85
Decreased by -65.95%
EPS Next Year
10.39
from 9.48
Increased by 9.56%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.7B | 2.8B | |||
| Avg | 2.6B | 2.7B | |||
| Low | 2.5B | 2.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.7% | 9.5% | |||
| Avg | 0.6% | 2.4% | |||
| Low | -4.0% | -4.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.76 | 12.17 | |||
| Avg | 9.48 | 10.39 | |||
| Low | 8.67 | 8.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -61.4% | 28.3% | |||
| Avg | -66.0% | 9.6% | |||
| Low | -68.9% | -9.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.